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REPLY
The comment by Harper and Haqqani, namely that a patent
foramen ovale (PFO) is unlikely to confer a significant mortality
disadvantage, indirectly acknowledges that it might. Paradoxical
embolism through a PFO can unequivocally have devastating
consequences, including death. Hence, even if no significant risk
for mortality has yet been proven, people die from it (1). This must
suffice to take the matter seriously. If there was a simple vaccina-
tion to close the PFO, it would be a world standard. Implantation
of a device in the heart, with an inherent risk for mortality as well,
needs proof of superiority over the natural course. This proof (or
disproof) is subject to time. About 1,000 patients have been
randomized between device closure and natural course in a variety
of trials in progress. Device implantation should show any disad-
vantage quite early as its risks are front-loaded. An advantage,
however, takes many years to unveil because events from a PFO are
fortunately rare (rarer than we initially thought), but not absent.
None of the trials has been stopped prematurely, which speaks
against a disadvantage without compromising the hope for an
advantage of PFO closure.
The theory of selective mortality of the PFO is indeed not in
keeping with the finding that the fewer PFOs in the elderly are
larger in size (2). The theory of late spontaneous fusion by
increasing left atrial pressure with age could explain that. Con-
versely, there is hard evidence for the first theory (people do die
from PFOs) but not for the second. The fact that patients with
mitral stenosis had a passable PFO in 1% according to Harper
and Haqqani is not sufficiently explained by either theory. The
bulging of the atrial septum into the right atrium in mitral stenosis
is likely to render catheter passage from the inferior vena cava more
difficult as the PFO is hidden behind this bulge in a region where
the septum now is tangential to the catheter path, making probing
for the PFO unyielding. Many PFOs go undetected under these
circumstances, although they are not fused but simply functionally
closed by elevated left atrial pressure and moved out of target for
access from the inferior vena cava.
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REPLY
We appreciate and acknowledge the interest in our recently reported
study (1). In regard to the comments of Schrale et al., we studied
subjects in age increments or “cells” of 10 years beginning at age 45,
and we did not find an increased stroke risk in even the younger age
cells. A recent case control study published by Petty et al. (2) supports
our finding that patent foramen ovale (PFO) does not appear to be a
risk factor for cryptogenic stroke in the general population.
Also, Harper and Haqqani provide intriguing thoughts regard-
ing the issue of PFO detection rates in older individuals. It is
possible that a PFO may close in older subjects, but this postulate
is based on many assumptions, including that older people have
elevated left atrial pressures. This is an interesting concept that
merits systematic evaluation.
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Coronary Plaque Burden
and Cardiovascular Risk Factors:
Single-Point Versus Serial Assessment
In their interesting study, Nicholls et al. (1) recently assessed in a
large series of patients the relation between various cardiovascular
risk factors and the amount of coronary plaque burden with
(non-serial) volumetric intravascular ultrasound (IVUS). In this set
of high-quality data, male gender, diabetes mellitus, and a history
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of revascularization were the only predictors of the extent of plaque
burden, whereas the established cardiovascular risk factor low-
density lipoprotein cholesterol (LDL-C) showed no statistically
significant relation to the amount of plaque burden (1).
Our group serially assessed left main stems of patients with
coronary artery disease treated by usual care with IVUS. Similar to the
findings of Nicholls et al. (1), at baseline (single-point observation) we
also found that patients with low versus high LDL-C levels had no
difference in coronary plaque burden (2). However, our patients with
high LDL-C levels showed significantly more plaque progression
during IVUS follow-up (serial observation) (2). Using these data, we
were able to show for the first time a significant linear relation
between LDL-C levels and coronary plaque progression as directly
measured by IVUS (2); later, this was confirmed by large pharmaco-
logical intervention trials with serial IVUS (3).
The aforementioned pieces of evidence suggest that the extent of
atherosclerotic plaque burden, as assessed at a single point in time,
does not sufficiently predict the rate of plaque progression during
follow-up. The extent of plaque burden can be in a balance between
plaque progression and regression. In other words, plaques may be
“progressors” despite a relatively small plaque burden, and plaques
may be “regressors” despite a relatively great plaque burden. This
underlies the fact that single-point observations are unable to charac-
terize the “dynamic status” of coronary lesions.
Coronary remodeling (changes in total vessel size) may be partly
responsible for the contradiction between the findings of single-point
versus serial assessment when analyzing percent plaque burden.
Plaque burden is in fact the relation between total vessel and plaque
size: if plaque size remains unchanged but vessel size decreases
(“negative remodeling”), the calculated percent plaque burden in-
creases; and if total vessel size increases (“positive remodeling”), plaque
burden decreases. Although the remodeling index shows a relatively
close relationship with the subsequent direction of true serial remod-
eling (4), we were unable to demonstrate a relation between plaque
burden and changes in total vessel dimensions (i.e., serial remodeling)
(5), which underlies the relative independence of actual coronary
remodeling from baseline plaque burden.
Finally, serial observational ultrasound data suggest that coro-
nary plaque progression by IVUS may be associated with increased
cardiovascular risk (6). We found that patients at the highest
estimated cardiovascular risk, as derived from 3 established cardio-
vascular risk scores, showed the highest plaque progression rates; in
addition, patients with greater plaque progression had significantly
more actual cardiovascular events during follow-up (6).
Thus, we believe that serial assessment of coronary plaques
(progression–regression)—if possible with volumetric analyses
(7)—should be the “gold standard” when analyzing the relation
between cardiovascular risk factors and coronary atherosclerosis.
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REPLY
We read with interest the letter by Drs. von Birgelen and
Hartmann with regard to our use of serial versus static assessments
of atheroma burden using intravascular ultrasound (IVUS) (1).
Although static assessments do not adequately evaluate the dy-
namic process of arterial wall remodeling, the ability to apply a
cross-sectional appraisal of a cohort of subjects provides a unique
opportunity to investigate factors that correlate with the extent of
atheroma throughout a coronary arterial segment. Serial assess-
ments of atheroma burden have assumed a pivotal role in the
elucidation of the factors, including pharmacological interventions,
that influence the natural history of atherosclerosis. It is for this
reason that the serial assessment of atheroma burden by IVUS has
become a surrogate end point in clinical trials (2–7).
The previous studies of the left main coronary artery cited by
these investigators (8) raise a number of important points with
regard to the study of atherosclerosis. A major limitation of these
studies includes their measurement of atheroma area at a single
cross-sectional slice of the left main coronary artery in a small
number of subjects (n  60), which were deemed to have the
smallest lumen area at baseline. As a result, these researchers used
the single image that corresponded to the most severe angiographic
stenosis in one specific segment of the coronary anatomy to make
speculative assessments of atherosclerosis. Given that atheroscle-
rosis is a systemic and not a focal process that would fit in a single
ultrasound frame, in addition to the well-established discord
between angiographic abnormalities and the extent of atheroma
within the arterial wall, it is uncertain what conclusions can be
made from investigating disease at one site.
The problem of using a single slice is further magnified in serial
studies. Serial assessment of atheroma burden requires precise
matching of that single slice, a task that is difficult to achieve in
many cases. In contrast, our report describes the relationship
between a broad range of clinical parameters and the volume of
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